CH Valence
About CH Valence
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Centre Hospitalier de Valence
9
Groupe Francophone des Myelodysplasies
7
MicroPort CRM
7
Hospices Civils de Lyon
6
The Lymphoma Academic Research Organisation
6
Biotronik SE & Co. KG
4
European Organisation for Research and Treatment of Cancer - EORTC
4
Federation Francophone de Cancerologie Digestive
4
Intergroupe Francophone de Cancerologie Thoracique
4
Celgene
3
Centre Hospitalier Universitaire de Saint Etienne
3
Clinical Trials at CH Valence
During the past decade, CH Valence conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 7 clinical trials were completed, i.e. on
average, 13.7% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 3 clinical trials were completed. i.e. 12%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
1998-10-01
Active, not recruiting
1,649
Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
1998-07-22
2007-09-01
Completed
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
2002-08-01
Completed
552
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
2005-09-01
Completed
835
Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
2003-06-01
2011-01-01
Completed
282
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
2008-03-01
2010-04-01
Terminated
54
A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q
2009-02-01
2015-12-01
Unknown status
85
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "CH Valence" #1 sponsor was "Centre Hospitalier de Valence" with 9 trials, followed by "Groupe Francophone des Myelodysplasies" with 7 trials
sponsored, "MicroPort CRM" with 7 trials sponsored, "Hospices Civils de Lyon" with 6 trials sponsored and "The Lymphoma Academic Research Organisation"
with 6 trials sponsored. Other sponsors include 71 different institutions and
companies that sponsored additional 52 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "CH Valence"
#1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "Federation Francophone de Cancerologie Digestive" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Janssen-Cilag Ltd." with 2 trials as a collaborator. Other collaborators include 44 different institutions and companies that were
collaborators in the rest 51 trials.
Clinical Trials Conditions at CH Valence
According to Clinical.Site data, the most researched conditions in "CH Valence" are
"Heart Failure" (5 trials), "Cancer" (4 trials), "Colorectal Cancer" (4 trials), "Coronary Artery Disease" (4 trials) and "Acute Coronary Syndrome" (3 trials). Many other conditions were trialed in "CH Valence" in a lesser frequency.
Clinical Trials Intervention Types at CH Valence
Most popular intervention types in "CH Valence" are "Drug" (48 trials), "Other" (17 trials), "Device" (16 trials), "Procedure" (7 trials) and "Biological" (6 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (5 trials), "Lenalidomide" (4 trials), "Rituximab" (3 trials), "fluorouracil" (3 trials) and "irinotecan hydrochloride" (3 trials). Other intervention names were less common.
Clinical Trials Genders at CH Valence
The vast majority of trials in "CH Valence" are
104 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.
Clinical Trials Status at CH Valence
Currently, there are NaN active trials in "CH Valence".
undefined are not yet recruiting,
23 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 67 completed trials in CH Valence,
undefined suspended trials,
and 6 terminated clinical trials to date.
Out of the total trials that were conducted in CH Valence, 2 "Phase 1"
clinical trials were conducted, 18 "Phase 2" clinical
trials and 29 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 3 trials, and there were
also 17 trials that are defined as “Not Applicable".